Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cintredekin besudotox
- Development stage
- Phase 3
- Lead developer
- Precision NeuroMed
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intracerebral, Convection-enhanced Delivery
01
Overview
Cintredekin besudotox is a recombinant chimeric protein developed as a specific tumor-targeting agent for the treatment of malignant gliomas, particularly glioblastoma multiforme (GBM). It consists of human interleukin-13 (IL-13), an immunoregulatory cytokine, linked to a truncated and mutated form of Pseudomonas exotoxin A (PE38QQR). The IL-13 portion binds to IL-13 receptors overexpressed on tumor cells but minimally present on normal brain tissue. Upon binding, the toxin is internalized and induces apoptosis in tumor cells. Cintredekin besudotox is administered directly into brain tissue at risk for residual infiltrating GBM after tumor resection using convection-enhanced delivery (CED), which allows high local concentrations while minimizing systemic exposure[1][2][4].
- Other names
- Interleukin-13-PE38QQR immunotoxinInterleukin13-PE38QQR immunotoxinInterleukin 13-PE38QQR immunotoxinCB
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on cintredekin besudotox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cintredekin besudotox.